Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Friday.

AXDX has been the topic of several other reports. BTIG Research lowered shares of Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 13th. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $33.00.

Shares of Accelerate Diagnostics (AXDX) opened at $29.10 on Friday. The company has a market cap of $1,610.00, a P/E ratio of -24.25 and a beta of 2.18. Accelerate Diagnostics has a 1 year low of $16.75 and a 1 year high of $30.45.

Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings results on Thursday, November 2nd. The medical research company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.01. Accelerate Diagnostics had a negative net margin of 3,085.36% and a negative return on equity of 60.99%. research analysts expect that Accelerate Diagnostics will post -1.22 EPS for the current fiscal year.

In other Accelerate Diagnostics news, Director Jack W. Schuler purchased 50,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average cost of $18.46 per share, for a total transaction of $923,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jack W. Schuler purchased 340,964 shares of the stock in a transaction dated Monday, November 6th. The stock was acquired at an average price of $18.51 per share, for a total transaction of $6,311,243.64. Following the completion of the transaction, the director now directly owns 44,670 shares of the company’s stock, valued at $826,841.70. The disclosure for this purchase can be found here. Insiders bought 487,645 shares of company stock worth $9,090,393 over the last quarter. Company insiders own 50.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in AXDX. Kornitzer Capital Management Inc. KS boosted its position in Accelerate Diagnostics by 37.3% during the third quarter. Kornitzer Capital Management Inc. KS now owns 530,219 shares of the medical research company’s stock worth $11,903,000 after acquiring an additional 144,055 shares during the last quarter. AXA boosted its position in Accelerate Diagnostics by 40.2% during the third quarter. AXA now owns 432,647 shares of the medical research company’s stock worth $9,713,000 after acquiring an additional 124,035 shares during the last quarter. FMR LLC boosted its position in Accelerate Diagnostics by 40.0% during the second quarter. FMR LLC now owns 420,072 shares of the medical research company’s stock worth $11,489,000 after acquiring an additional 120,072 shares during the last quarter. Strs Ohio acquired a new stake in Accelerate Diagnostics during the third quarter worth approximately $2,394,000. Finally, Artemis Investment Management LLP acquired a new stake in Accelerate Diagnostics during the third quarter worth approximately $2,245,000. Hedge funds and other institutional investors own 47.77% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://theolympiareport.com/2018/02/02/accelerate-diagnostics-axdx-upgraded-by-valuengine-to-hold.html.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.